Display, engineering, and applications of antigen-specific T cell receptors

Sarah A. Richman, David M Kranz

Research output: Contribution to journalReview article

Abstract

The use of T cell receptors (TCRs) as potential therapeutic agents provides an opportunity to target a greatly expanded array of antigens, compared to those now targeted with monoclonal antibodies. With the advent of new display technologies and TCR formats for in vitro engineering, it should be possible to generate high-affinity TCRs against virtually any peptide antigen that is shown to bind to a major histocompatibility complex (MHC) molecule (e.g. peptides derived from viral antigens or from self proteins that are associated with the transformed phenotype). What remains, however, are challenges associated with effective targeting of very low numbers of cell surface antigens (pepMHC), fewer than the case for conventional monoclonal antibody-based therapies. This hurdle might be overcome with the attachment of more effective payloads for soluble TCR approaches, or by using TCR gene transfer into T cells that can then be adoptively transferred into patients. There is considerable work to be done on the physiological aspects of either approach, including pharmacokinetic studies in the case of soluble TCRs, and T cell trafficking, persistence, and autoreactivity studies in the case of adoptively transferred T cells. As with the field of monoclonal antibodies, it will take time to explore these issues, but the potential benefits of TCR-based therapies make these challenges worth the effort.

Original languageEnglish (US)
Pages (from-to)361-373
Number of pages13
JournalBiomolecular Engineering
Volume24
Issue number4
DOIs
StatePublished - Oct 1 2007

Fingerprint

T-cells
Antigens
T-Cell Antigen Receptor
Display devices
Monoclonal Antibodies
Monoclonal antibodies
T-Lymphocytes
T-Cell Receptor Genes
Peptides
Viral Antigens
Gene transfer
Surface Antigens
Pharmacokinetics
Major Histocompatibility Complex
Therapeutics
Technology
Phenotype
Molecules
Proteins

Keywords

  • Antigens
  • High-affinity T cell receptors
  • Monoclonal antibodies
  • Peptide-major histocompatibility complex
  • T cell immunity
  • Tumor targeting

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Molecular Biology

Cite this

Display, engineering, and applications of antigen-specific T cell receptors. / Richman, Sarah A.; Kranz, David M.

In: Biomolecular Engineering, Vol. 24, No. 4, 01.10.2007, p. 361-373.

Research output: Contribution to journalReview article

@article{dd998da81194490580744d93b820b776,
title = "Display, engineering, and applications of antigen-specific T cell receptors",
abstract = "The use of T cell receptors (TCRs) as potential therapeutic agents provides an opportunity to target a greatly expanded array of antigens, compared to those now targeted with monoclonal antibodies. With the advent of new display technologies and TCR formats for in vitro engineering, it should be possible to generate high-affinity TCRs against virtually any peptide antigen that is shown to bind to a major histocompatibility complex (MHC) molecule (e.g. peptides derived from viral antigens or from self proteins that are associated with the transformed phenotype). What remains, however, are challenges associated with effective targeting of very low numbers of cell surface antigens (pepMHC), fewer than the case for conventional monoclonal antibody-based therapies. This hurdle might be overcome with the attachment of more effective payloads for soluble TCR approaches, or by using TCR gene transfer into T cells that can then be adoptively transferred into patients. There is considerable work to be done on the physiological aspects of either approach, including pharmacokinetic studies in the case of soluble TCRs, and T cell trafficking, persistence, and autoreactivity studies in the case of adoptively transferred T cells. As with the field of monoclonal antibodies, it will take time to explore these issues, but the potential benefits of TCR-based therapies make these challenges worth the effort.",
keywords = "Antigens, High-affinity T cell receptors, Monoclonal antibodies, Peptide-major histocompatibility complex, T cell immunity, Tumor targeting",
author = "Richman, {Sarah A.} and Kranz, {David M}",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.bioeng.2007.02.009",
language = "English (US)",
volume = "24",
pages = "361--373",
journal = "New Biotechnology",
issn = "1871-6784",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Display, engineering, and applications of antigen-specific T cell receptors

AU - Richman, Sarah A.

AU - Kranz, David M

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The use of T cell receptors (TCRs) as potential therapeutic agents provides an opportunity to target a greatly expanded array of antigens, compared to those now targeted with monoclonal antibodies. With the advent of new display technologies and TCR formats for in vitro engineering, it should be possible to generate high-affinity TCRs against virtually any peptide antigen that is shown to bind to a major histocompatibility complex (MHC) molecule (e.g. peptides derived from viral antigens or from self proteins that are associated with the transformed phenotype). What remains, however, are challenges associated with effective targeting of very low numbers of cell surface antigens (pepMHC), fewer than the case for conventional monoclonal antibody-based therapies. This hurdle might be overcome with the attachment of more effective payloads for soluble TCR approaches, or by using TCR gene transfer into T cells that can then be adoptively transferred into patients. There is considerable work to be done on the physiological aspects of either approach, including pharmacokinetic studies in the case of soluble TCRs, and T cell trafficking, persistence, and autoreactivity studies in the case of adoptively transferred T cells. As with the field of monoclonal antibodies, it will take time to explore these issues, but the potential benefits of TCR-based therapies make these challenges worth the effort.

AB - The use of T cell receptors (TCRs) as potential therapeutic agents provides an opportunity to target a greatly expanded array of antigens, compared to those now targeted with monoclonal antibodies. With the advent of new display technologies and TCR formats for in vitro engineering, it should be possible to generate high-affinity TCRs against virtually any peptide antigen that is shown to bind to a major histocompatibility complex (MHC) molecule (e.g. peptides derived from viral antigens or from self proteins that are associated with the transformed phenotype). What remains, however, are challenges associated with effective targeting of very low numbers of cell surface antigens (pepMHC), fewer than the case for conventional monoclonal antibody-based therapies. This hurdle might be overcome with the attachment of more effective payloads for soluble TCR approaches, or by using TCR gene transfer into T cells that can then be adoptively transferred into patients. There is considerable work to be done on the physiological aspects of either approach, including pharmacokinetic studies in the case of soluble TCRs, and T cell trafficking, persistence, and autoreactivity studies in the case of adoptively transferred T cells. As with the field of monoclonal antibodies, it will take time to explore these issues, but the potential benefits of TCR-based therapies make these challenges worth the effort.

KW - Antigens

KW - High-affinity T cell receptors

KW - Monoclonal antibodies

KW - Peptide-major histocompatibility complex

KW - T cell immunity

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=34548592046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548592046&partnerID=8YFLogxK

U2 - 10.1016/j.bioeng.2007.02.009

DO - 10.1016/j.bioeng.2007.02.009

M3 - Review article

C2 - 17409021

AN - SCOPUS:34548592046

VL - 24

SP - 361

EP - 373

JO - New Biotechnology

JF - New Biotechnology

SN - 1871-6784

IS - 4

ER -